CAR-T Cell Therapy Receives FDA Breakthrough Designation – Pharmaceutical Processing
Pharmaceutical Processing |
CAR–T Cell Therapy Receives FDA Breakthrough Designation
Pharmaceutical Processing Novartis announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and … |
